Novel Therapies for Metastatic Triple-Negative Breast Cancer: Spotlight on Immunotherapy and Antibody-Drug Conjugates

Medicine & Life Sciences

• Immunoconjugates 100%
• Triple Negative Breast Neoplasms 90%
• Immunotherapy 65%
• atezolizumab 39%
• olaparib 38%
• pembrolizumab 35%
• sacituzumab govitecan 25%
• Combination Drug Therapy 25%
• talazoparib 23%
• Poly(ADP-ribose) Polymerase Inhibitors 16%
• Breast Neoplasms 15%
• Germ-Line Mutation 14%
• Precision Medicine 13%
• Progesterone Receptors 13%
• Phosphatidylinositol 3-Kinases 12%
• Therapeutics 12%
• Estrogen Receptors 11%
• Anti-Idiotypic Antibodies 10%
• Hormones 8%
• Neoplasms 8%
• Drug Therapy 7%
• Survival 6%